Data gathered: November 7
Alternative Data for Merck & Company
About Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
| Price | $100.73 |
| Target Price | Sign up |
| Volume | 9,500,000 |
| Market Cap | $258B |
| Year Range | $100.73 - $132.1 |
| Dividend Yield | 3.02% |
| PE Ratio | 21.31 |
| Analyst Rating | 84% buy |
| Industry | Drug Manufacturers |
In the news
 |
Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy Right Now?November 4 - Yahoo |
Merck & Company: Overcoming Challenges with Strategic Growth ProspectsOctober 31 - TipRanks |
|
 |
Merck & Co Inc (MRK) Q3 2024 Earnings Call Highlights: Strong Oncology and Animal Health ...October 31 - Yahoo |
Merck & Company: Navigating One-Time Charges and Uncertainty in Gardasil Sales Amidst Strategic ShiftsOctober 31 - TipRanks |
|
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT) and Merck & Company (MRK)October 31 - TipRanks |
|
MRK Earnings: Merck Stock Drops Despite Q3 BeatOctober 31 - TipRanks |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 16.1B | 6.41B | 9.71B | 5.46B | 7.33B | 2.280 |
| Q1 '24 | 15.8B | 5.99B | 9.79B | 4.76B | 6.74B | 2.070 |
| Q4 '23 | 14.6B | 9.62B | 5.01B | -1.23B | 679M | 0.030 |
| Q3 '23 | 16B | 6.77B | 9.19B | 4.75B | 7.2B | 2.130 |
| Q2 '23 | 15B | 6.77B | 8.27B | -5.98B | -3.77B | -2.060 |
Insider Transactions View All
| Davis Robert M filed to sell 348,327 shares at $125.4. February 15 '24 |
| Litchfield Caroline filed to sell 50,908 shares at $125.5. February 15 '24 |
| Romanelli Joseph filed to sell 19,569 shares at $124.9. February 14 '24 |
| Davis Robert M filed to sell 348,327 shares at $126.4. February 15 '24 |
| Davis Robert M filed to sell 373,651 shares at $125.7. February 15 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$157.88 0% | 50 |
 |
Eli Lilly and CompanyLLY |
$776.38 0% | 63 |
 |
PfizerPFE |
$27.36 0% | 40 |
 |
AstrazenecaAZN |
$63.85 0% | 64 |
 |
AbbVieABBV |
$201.2 0% | 56 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Jonathan Jackson |
Oct 14, 24 | Sell | $15K - $50K |
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
| John James |
Sep 2, 24 | Buy | $1K - $15K |
Read more about Merck & Company (MRK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Merck & Company?
The Market Cap of Merck & Company is $258B.
What is Merck & Company's PE Ratio?
As of today, Merck & Company's PE (Price to Earnings) ratio is 21.31.
What is the current stock price of Merck & Company?
Currently, the price of one share of Merck & Company stock is $100.73.
How can I analyze the MRK stock price chart for investment decisions?
The MRK stock price chart above provides a comprehensive visual representation of Merck & Company's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Merck & Company shares. Our platform offers an up-to-date MRK stock price chart, along with technical data analysis and alternative data insights.
Does MRK offer dividends to its shareholders?
Yes, Merck & Company (MRK) offers dividends to its shareholders, with a dividend yield of 3.02%. This dividend yield represents Merck & Company's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Merck & Company in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Merck & Company?
Some of the similar stocks of Merck & Company are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.